NHL Recruiting Phase 1 Trials for Blinatumomab (DB09052)

Also known as: Lymphomas: Non-Hodgkin / Non Hodgkin´s Lymphomas / Lymphoma, Non-Hodgkin (NHL) / NHL - Non-Hodgkin's Lymphoma / NHL (Non-Hodgkin Lymphoma) / Lymphoma,Non-Hodgkin / Non-Hodgkin's Disease / Lymphoma, Non-Hodgkin;Hodgkin Disease / Non Hodgkin Lymphoma / Non Hodgkin's Lymphoma / Lymphoma, Non Hodgkin / Non Hodgkin Lymphoma (NHL) / Non-Hodgkin / Non-Hodgkin's Lymphomas / Non-Hodgkin Lymphoma / Non-Hodgkin Lympoma / Non-Hodgkins Lymphoma (NHL) / Non-Hodgkin-Lymphoma / Lymphoma, Non-Hodgkin's / Non Hodgkins Lymphoma / Non-Hodgkin Lymphomas / Lymphoma, Non-Hodgkin / Non-Hodgkin's Lymphoma(NHL) / Non-Hodgkin's Lymphoma (NHL) / Lymphoma. Non-Hodgkin / Non-Hodgkin's Lymphoma / Non-Hodgkins Lymphoma / Lymphoma Non-Hodgkin / Non-Hodgkins's Lymphoma / Non-Hodgkin’s lymphoma / Lymphoma, Non-Hodgkins / Non-Hodgkins / Non-Hodgkin Lymphoma (NHL) / Non-Hodgkin's Lymphoma or Hodgkin's Disease / Lymphoma NOS / Histiocytosis X / Non-Hodgkin's lymphoma NOS / Lymphoma (non-Hodgkin's)

IndicationStatusPhase
DBCOND0035368 (NHL)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02961881A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's LymphomaTreatment